Full Press Release Details
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure.
LXRX
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
Key Takeaway: Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
Price reaction · baseline $1.74 (2022-05-27 close) · hit after-hours · 1 other LXRX headline(s) in the window, move may be shared
day 0 close
+1.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus